Total trials
242
Active
25
Phase 3
17
Total enrollment
23,120
Pipeline matrix
Showing 11 of 11 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ketamine | — | — | — | — | 3 | ||
| Tiotropium | — | — | — | — | — | 2 | |
| IV iron | — | — | — | — | — | 1 | |
| FOLFOXIRI and Bevacizumab | — | — | — | — | — | 1 | |
| IRE plus checkpoint inhibitor | — | — | — | — | — | 1 | |
| IRE plus Checkpoint Inhibitor plus CpG-ODN | — | — | — | — | — | 1 | |
| IRDye800CW-nimotuzumab | — | — | — | — | — | 1 | |
| NeuroEPO | — | — | — | — | — | 1 | |
| 50 mg 89Zr-DFO-Nimotuzumab | — | — | — | — | — | 1 | |
| 1 mg 89Zr-DFO-Nimotuzumab | — | — | — | — | — | 1 | |
| Cannabidiol | — | — | — | — | — | 1 |
Next readouts
- 2025-11
- 2025-12-31
- 2026-09
- 2026-09
- 2026-12-31
- 2027-01
- 2027-12
- 2028-12-01
- 2030-03
Top conditions
- Asthma20
- Osteoporosis10
- Sarcopenia8
- Pain7
- Coronary Artery Disease6
- Multiple Sclerosis5
- Depression5
- Fall Injury4
Frequently asked questions about University of Saskatchewan
- How many clinical trials does University of Saskatchewan have on ClinicalTrials.gov?
- University of Saskatchewan is listed as the lead sponsor on 242 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Saskatchewan's trials are in Phase 3?
- 17 of University of Saskatchewan's trials are in Phase 3, spread across 11 active drug programs.
- What therapeutic areas does University of Saskatchewan focus on?
- University of Saskatchewan's most-studied conditions on ClinicalTrials.gov are Asthma, Osteoporosis, Sarcopenia, Pain, Coronary Artery Disease.
- When are University of Saskatchewan's next clinical trial readouts?
- University of Saskatchewan has 9 upcoming primary-completion readouts tracked here; the soonest is “Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults”, expected around 2025-11.